Chronic gamma-butyrolactone (GBL) treatment: a potential model of dopamine hypoactivity.
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D015107:4-Butyrolactone / Q000494:pharmacology*; D000818:Animals; D004298:Dopamine / Q000378:metabolism / Q000502:physiology*; D004361:Drug Tolerance; D005663:Furans / Q000494:pharmacology*; D008297:Male; D008960:Models, Psychological; D009043:Motor Activity / Q000187:drug effects*; D051381:Rats; D011954:Receptors, Dopamine / Q000187:drug effects; D012890:Sleep / Q000187:drug effects*; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
D005663:Furans; D011954:Receptors, Dopamine; D015102:3,4-Dihydroxyphenylacetic Acid; D014446:Tyrosine 3-Monooxygenase; D015107:4-Butyrolactone; D004298:Dopamine